SLAS is pleased to announce the Board of Directors approved the slate of candidates for the 2019 Board of Directors at its November meeting. Each new board member will join the SLAS Board of Directors for three-year terms beginning at SLAS2019, February 2-6, in Washington, DC.
A new study published ahead-of-print by SLAS Discovery describes an evaluation of microplate-based high-throughput cellular thermal shift assay (CETSA HT) performed at AstraZeneca to assess its suitability and reliability for application to early drug discovery campaigns.
A study in the December 2018 issue of SLAS Technology demonstrates the feasibility of using a steady-state/lifetime fluorescence plate reader for direct optimization of challenging formulation conditions and highlights the importance of performing formulation optimization under commercially relevant conditions.
Researchers from the University of Manchester (United Kingdom) explore recent developments and strategies for targeting the NLRP3 inflammasome as a potential therapeutic target in acute and chronic neurological and neurodegenerative diseases, and offer perspective on how this field may develop in the future.
SLAS, the Society for Laboratory Automation and Screening, has selected 50 students from 12 countries to present their research at SLAS2019 as the most recent winners of the SLAS Tony B. Academic Travel Award. These notable undergraduate students, graduate students, post-doctoral researchers and junior faculty members were selected by an independent panel of judges who evaluated their abstract proposals based on scientific merit and potential impact of the research toward the advancement of life sciences discovery and technology.
A new auto-commentary looks at how an emerging area of artificial intelligence, specifically the analysis of small systems-of-interest specific datasets, can be used to improve drug development and personalized medicine.
The internet of things (IoT) is allowing scientists to optimize laboratory operations and combine instruments to measure and respond to complex experimental conditions. As a result, IoT is enabling more detailed and more complex experimental designs.
A new review in SLAS Discovery explores how improved safety screening strategies and methods are improving the pharmaceutical discovery and development process. The authors outline several fundamental methods of the current drug screening processes and emerging techniques and technologies that promise to improve molecule selection. In addition, the authors discuss integrated screening strategies and provide examples of advanced screening paradigms.
Michael Tarselli, Ph.D., will join the Society for Laboratory Automation and Screening (SLAS) as its new Scientific Director, beginning September 1.
A new special issue of SLAS Discovery reflects examples of the recent groundswell of creative new applications for high-throughput flow cytometry (HTFC) in drug discovery.
Technologies that are reducing costs and changing the ways in which researchers and clinicians process and use therapeutic cells are showcased in the August 2018 special issue of SLAS Technology.
A time-resolved fluorescence resonance energy transfer-based BTK occupancy assay measures target engagement in peripheral blood mononuclear cells (PBMCs) and in lymph-node and bone-marrow samples.
To aid in the discovery and understanding of lncRNA biology, newly published work features the technological platforms and methodology presently used to identify the roles of lncRNA in biology. This work highlights the databases and tools used to study lncRNA and techniques used to study their function.
SLAS has selected Kelci Schilly, a graduate research assistant in the Department of Chemistry at the University of Kansas (Lawrence, KS, USA), as the inaugural recipient of the 2018 SLAS Visiting Graduate Researcher Grant, and will cover her three-month visit to the laboratory of SLAS President Sabeth Verpoorte, Ph.D., at the University of Groningen (The Netherlands).
A new SLAS Discovery review article summarizes new methods of fragment-based lead discovery (FBLD) to identify new compounds as potential antibiotics. It explains how FBLD works and illustrates its advantages over conventional high-throughput screening.
A new SLAS Discovery review article by GlaxoSmithKline researchers in the U.S. and U.K. offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.
New research describes the development of a novel screening platform with automated production of 3D muscle- and tendon-like tissues using 3D bioprinting.
Researchers at Coyne Scientific (Atlanta, GA) share perspective about Clinical Trials in a Dish (CTiD), a novel strategy that bridges preclinical testing and clinical trials.
New research highlights a diversity of approaches that automated high-throughput flow cytometry has enabled for phenotypic drug discovery.
The June 2018 special issue of SLAS Technology provides a meaningful glimpse into the potential and applicability of quantitative imaging as life sciences and biomedical research move into an era of big data and high-content experiments.
The June issue of SLAS Discovery features two special collections of articles that address important trends for the advancement of life sciences R&D. Both collections include robust editorials by the guest editors, offering informed thoughts about the challenges and opportunities presented by these influential topics.
This vision of simplifying disease diagnosis using topically-applied nanotechnology could change the way skin diseases such as abnormal scars are diagnosed and managed.
In a new SLAS Discovery auto-commentary, two authors of an article recently published in eLife (“LINE-1 Protein Localization and Functional Dynamics During the Cell Cycle”) explain their general views on their novel discoveries and discuss ideas on the relevant new questions generated by their data.
A multidisciplinary team of scientists share recent advancements in innovative in-vitro cancer biology methods for screening drug-like molecules in cancer tissue relevant models in a new report published online ahead-of-print at SLAS Discovery. Entitled Advanced Development of Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug Screening, the report can be accessed for free.
Santosh Paidi, a graduate research assistant in the Department of Mechanical Engineering and at Johns Hopkins University, has been selected as the 2018 recipient of the SLAS Graduate Education Fellowship Grant. The $100,000 SLAS fellowship grant, awarded over two years, allows Paidi to continue his work in the lab of Ishan Barman, Ph.D., which employs vibrational spectroscopy and recent improvements in areas such as optics, nanotechnology and computing, to develop improved diagnostic tools that can provide rapid, robust, quantitative and molecular-specific readouts from biological specimen.
A new original research report available ahead-of-print at SLAS Technology demonstrates the semi-automation of a GlycoWorks RapiFluor-MS (RFMS) Kit using a pipetting robot to improve life sciences research productivity.
In the April 2018 issue of SLAS Technology, Breitwieser and colleagues of the Karlsruhe Institute of Technology (Germany) describe a fully automated high-throughput sorting system for zebrafish embryo phenotypes that benefits high-throughput screening by saving time and improving accuracy.
A review article by Prof. Stefan Broer, Ph.D., highlights opportunities and challenges in using amino acid transporters as drug targets. Amino Acid Transporters as Disease Modifiers and Drug Targets provides an overview of methods used to identify new inhibitors for amino acid transporters and outlines cell and organ function where these can be used to modulate, prevent or to treat diseases.
A perspective article in the March 2018 issue of SLAS Discovery from the biology group at the European Screening Centre Newhouse details how the European Lead Factory (ELF), a large publicly accessible drug discovery platform, uses microscale thermophoresis (MST) to aid in the prioritization of small molecule hits from high-throughput screening.
Three organizations earned a SLAS New Product Award yesterday at SLAS2018 in San Diego for their innovative new productsthat have played an important role in the advancement of life sciences drug discovery and development.
SLAS2018 was all about science and innovation as new keynote lectures, cutting-edge podium presentations and the new SLAS Ignite Theater series stoked the collaborative nature of today's life sciences professionals with three days of ground-breaking presentations that left attendees pondering new ways to keep pace with the speed of science.
SLAS Discovery (formerly the Journal of Biomolecular Screening) and SLAS Technology (formerly the Journal of Laboratory Automation), both published by SLAS (Society of Laboratory Automation and Screening) in partnership with SAGE Publishing, hosted a special reception to celebrate the 2018 SLAS Journal Achievement Award honorees on Feb. 6 at SLAS2018, the SLAS International Conference and Exhibition, held Feb. 3-7, 2018, in San Diego, CA.
A phenotypic high-throughput screen to identify modulators that improve mutant cystic fibrosis transmembrane conductance regulator (CFTR) activity is described in the SLAS Discovery February 2018 front cover feature article by Giuliano and colleagues of Proteostasis Therapeutics, Inc. (Cambridge, MA).
“The 2018 SLAS Technology Ten represent some of the most innovative scientific achievements that were featured in SLAS Technology in the past 12 months,” says Editor-in-Chief Edward Kai-Hua Chow, PhD (National University of Singapore).
Life sciences professionals and business development dealmakers from all walks of industry, academia and government have a new interchange at SLAS2018 – SLAS Ignite, a series of programs that foster scientific innovation through collaboration, debuts at the 2018 SLAS International Conference and Exhibition (SLAS2018), Feb. 3-7, in San Diego, CA.
A new article in the February 2018 issue of SLAS Technology describes a new platform that could change the way cancer is diagnosed and treated by automating the isolation of circulating tumor cells (CTCs) directly from cancer patient blood. This article provides unique insight into the development of a commercial system that has the potential to change the standard of care in cancer diagnosis and treatment.
A new original research article in SLAS Discovery presents a fast, sensitive, and robust methodology for screening small molecule inhibitors against CD73/Ecto-5’-Nucleotidase, a promising target for developing anti-cancer drugs.